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Summary. Background: Well known risk factors for upper
extremity deep venous thrombosis are the presence of a central
venous catheter (CVC) andmalignancy, but other potential risk
factors, such as surgery, injury and hormone replacement
therapy (HRT), have not yet been explored. Methods: We
performed a population-based case-control study including 179
consecutive patients, aged 18–70 years with upper extremity
deep venous thrombosis and 2399 control subjects. Participants
reportedonacquired risk factors in aquestionnaire and factorV
Leiden and prothrombin 20210A mutation were ascertained.
Information on CVC was obtained from discharge letters.
Results: Forty-two patients (23%) and one control subject
(0.04%) had a CVC (ORadj: 1136, 95%CI: 153–8448, adjusted
for age and sex). Cancer patients without a CVC had an
eightfold increased risk of venous thrombosis of the arm
(ORcrude: 7.7, 95%CI: 4.6–13.0).Other evident risk factorswere
prothrombotic mutations, surgery, immobilization of the arm
(plaster cast), oral contraceptive use and family history, with
odds ratios varying from 2.0 up to 13.1. The risk in the presence
of injuryandduringpuerperiumwas twofoldormore increased,
although not significantly. In contrast HRT, unusual exercise,
travel and obesity did not increase the risk. Hormone users had
an increased risk in the presence of prothromboticmutations or
surgery. Obese persons (BMI > 30 kg m)2) undergoing sur-
gery had a 23-fold increased risk of arm thrombosis compared
with non-obese persons not undergoing surgery. Conclusion:A
CVC is a very strong risk factor for arm thrombosis. Most risk
factors for thrombosis in the leg are also risk factors for arm
thrombosis.
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Introduction
The annual incidence of venous thrombosis is 0.1% increasing
with age to 1% [1]. Approximately 4% of all cases of venous
thrombosis are located in the arm [2]. Complications associated
with upper extremity venous thrombosis are pulmonary
embolism (11–26%) [3], superior vena cava syndrome
(21–23%) [4,5] and postthrombotic syndrome (27–50%) [3,6].
Known risk factors for deep venous thrombosis of the arm
differ from risk factors of venous thrombosis of the leg or
pulmonary embolism. Central venous catheters (CVCs) con-
tribute to the risk of upper extremity venous thrombosis in
7–41% of all cases [7–10]. Other specific risk factors are effort-
related compression of the deep veins of the upper extremity
and compression caused by the thoracic outlet syndrome
(Paget–Schroetter syndrome) [3]. Risk factors for venous
thrombosis of the leg or pulmonary embolism, i.e. malignancy,
use of oral contraceptives, pregnancy and thrombophilia have
also been described as a risk factor for venous thrombosis of
the arm [10–12]. However, most studies on arm thrombosis
were of limited size and have not examined many of the other
risk factors known to affect leg thrombosis, such as surgery,
injury and hormone replacement therapy (HRT), as well as
immobilization, travel, obesity and puerperium.
The occurrence of a venous thrombotic event often depends
on the presence ofmore thanone risk factor simultaneously and
on the interactionbetween risk factors [13].Most patientswith a
CVC also have cancer. CVCs are used to administer chemo-
therapy or other drugs. Irritation of the vessel wall by the
chemotherapeutic agent inaddition to thehypercoagulable state
because of malignancy may add to the increased risk caused by
the CVC. Likewise, additional presence of acquired and genetic
risk factors, such as a CVC and the factor (F)V Leiden
mutation, could increase the risk of thrombosis even more.
In the Multiple Environmental and Genetic Assessment of
risk factors for venous thrombosis study (MEGA-study), a
large population-based case–control study evaluating risk
factors for venous thrombosis we included 179 unselected,
consecutive patients with upper extremity deep venous throm-
bosis. We assessed the effect of acquired and genetic risk
factors, which are highly prevalent. Additionally, we investi-
gated the risk in the joint presence of FV Leiden, the
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prothrombin 20210A mutation and malignancy and other
known risk factors of venous thrombosis.
Methods
Patient inclusion
This studywas performedwithin theMEGA study, an ongoing
large population-based case–control study. The design of the
MEGA study is described in detail elsewhere [14]. In the
MEGA study consecutive patients aged 18–70 years, with a
first deep venous thrombosis of the leg or arm or a first
pulmonary embolism were included. Patients were identified at
six anticoagulation clinics in the Netherlands. Anticoagulation
clinics monitor the anticoagulant therapy of all patients in a
well-defined geographical area, which allowed the identification
of consecutive, unselected patients with venous thrombosis.
From March 1999 until September 2003, 181 consecutive
patients had a first deep venous thrombosis of the arm. One
patient died of cancer soon after the venous thrombosis. All
other 180 patients were invited to participate in our study. One
patient refused to participate, thus 179 patients were included
in the study leading to a response rate of 99.4%.
Discharge letters, collected from the general practitioner or
from the hospital in which patients had been treated for venous
thrombosis, were used to check for diagnostic methods. For
87% of the patients (n ¼ 156) a discharge letter could be
obtained. For 124 patients an objective diagnosis was docu-
mented. The diagnosis was objectively confirmed by ultrasound
(119 patients), contrast venography (two patients) and com-
puted tomography (three patients). For 32 patients we could
not retrieve information on diagnostic methods from the
discharge letter. These patients and those without a discharge
letter (n ¼ 23) were treated for at least 3 months with oral
anticoagulants and were included in the analysis.
Of the 179 participating patients, 169 had venous thrombosis
of the arm only, and nine cases (5%) also had a pulmonary
embolism. The latter were objectively diagnosed using venti-
lation-perfusion scintigraphy. One patient had venous throm-
bosis of the arm in combination with venous thrombosis of the
leg, confirmed by ultrasonography.
Control subjects were partners of patients with venous
thrombosis, aged 18–70 years without a history of venous
thrombosis, participating in the overall MEGA study from
March 1999 until November 2002. Of all participating patients,
75% had a partner of whom 79% participated as control
subject (n ¼ 2399) [14].
Data collection
All participants were asked to fill in a questionnaire on
acquired risk factors for venous thrombosis within a few weeks
after the thrombotic event, and were subsequently seen for a
blood draw 3 months after discontinuation of the anticoagu-
lant therapy. When the participant was unable to fill in the
questionnaire we asked questions by phone, using a standard
mini-questionnaire (one patient and 62 control subjects). We
used the date of diagnosis of thrombosis as the index date for
patients. For control subjects the index date was the date of
diagnosis of thrombosis of their partner (patient). Questions
about acquired risk factors, such as surgery, immobilization by
plaster cast, injury, unusual exercise (decorating, unusual heavy
gardening, sawing, chopping wood was specifically asked for)
and travel by car, bus, train or plane for more than 4 h were
included in the analysis for a time window of 3 months prior to
the index date. Injury was defined as rupturing or bruising of
muscles or tendons, repetitive strain injury, tenosynovitis or
bursitis. A history of malignancy, weight and height, use of oral
contraceptives or HRT, pregnancy, puerperium (defined as a
period of 3 months after delivery) at the index date, family
history (defined as having one or both parents with a history of
venous thrombosis before the age of 50) was also recorded in
the questionnaire. We defined a diagnosis of malignancy
5 years or less before the index date as active cancer [14].
Patients with absence of surgery in the previous 3 months,
absence of CVC in the previous month, absence of active
cancer, absence of puerperium, oral contraception, injury,
plaster cast or prothromboticmutationwere defined as patients
with idiopathic thrombosis of the arm.
Because we expected CVCs and cancer to be the most
important risk factors, we took efforts to obtainmore elaborate
information on these items. Information about the presence or
absence of a CVC in the month prior to the index date was
obtained from the discharge letters of patients. To obtain this
information from control subjects, we sent a short question-
naire to the general practitioner of those subjects who indicated
a hospital admission or surgery within 3 months prior to the
index date (n ¼ 61). If a discharge letter or information from
the general practitioner was unavailable or inconclusive we
interviewed the participant by telephone (20 patients and nine
control subjects). We received information for 98% of the
patients and 97% of the control subjects. For participants
without information we assumed absence of a CVC.
For individuals who indicated they had been diagnosed with
cancer, additional information regarding origin of the cancer
and stage of disease was gathered from their physician.
Participants with non-invasive skin cancer were not considered
as cancer patients (none of the patients and 21 control subjects).
For the patient who died soon after the venous thrombosis as
well as for patients and control subjects who refused to
participate (n ¼ 1 and 540, respectively), we verified the
diagnosis of cancer by information available from the antico-
agulation clinic or by phone [14].
All participants filled in an informed consent form and gave
permission to obtain information about their medical history.
This study was approved by the Ethics Committee of the
Leiden University Medical Center.
Blood collection and laboratory analysis
Blood samples were taken 3 months after discontinuation of
anticoagulant therapy. DNA was isolated to ascertain the FV
2472 J. W. Blom et al
 2005 International Society on Thrombosis and Haemostasis
Leiden mutation (G1691A, gene ID:2153) or the prothrombin
G20210A mutation (gene ID:5624). From persons who were
unable to give a blood sample and from participants included
from June 2002 onwards, we obtained a buccal swab, sent by
mail, for DNA analysis.
Blood samples were drawn into vacuum tubes containing
0.1 volume 0.106 mol L)1 trisodium citrate as anticoagulant.
The blood sample was separated into plasma and cells through
centrifugation. Using a salting-out method, high molecular
weight DNA was extracted. This was stored at )20 C until
amplification. DNA-analysis for the FV Leiden mutation and
the prothrombin mutation was performed using a combined
PCR method. Assessment of these mutations in DNA
retrieved from the buccal swabs was performed identically to
the method for DNA obtained from whole blood. A detailed
description of this method is described previously [14]. DNA
was available for 144 patients and 2018 control subjects.
Potential risk factors measured in blood plasma such as high
factor VIII levels, have not been investigated in the present
study.
Statistical analyses
Odds ratios (OR) were calculated as an approximation of
relative risks. The OR indicate the relative risk of venous
thrombosis in the presence of a risk factor relative to the
absence of that risk factor. A 95% confidence interval is given
according to the method of Woolf [15]. Using a multiple
logistic regression model, OR were adjusted for age and sex
(ORadj). In an extra analysis the risk of surgery, immobilization
(plaster), injury and active cancer was adjusted for each of these
factors by using a multivariable logistic regression model.
In the analysis of the effect of advanced stage of cancer,
different types of cancer, and the joint presence of cancer and
the FVLeidenmutation or the prothrombin 20210Amutation,
cancer patients are those with active cancer. Patients with
cancer diagnosed longer than 5 years ago were excluded from
these particular analyses.
To assess the effect of two risk factors simultaneously, OR
were calculated in the presence of only one risk factor and in
the presence of both risk factors, both relative to those with
neither risk factor present. SPSS for Windows version 12.0.1
(SPSS Inc., Chicago, IL, USA) was used for all statistical
analyses.
Results
The 179 patients with deep venous thrombosis of the arm and
2399 control subjects had a median age of, respectively 45.1
(5th–95th percentile: 20.5–67.2) and 50.2 (5th–95th percentile:
28.4–66.4) years. There were 100 women (55.9%) in the patient
group and 1202 women (50.1%) in the control group. In 56%
of the patients the left arm was involved and in 44% the right
arm. There were 17 patients with idiopathic thrombosis.
Central venous catheter
Patients with a CVC (42 of 179) had a highly increased risk to
develop deep venous thrombosis of the arm (ORadj 1136, 95%
CI: 153–8448; Table 1). Thirty patients had a CVC for the
administration of chemotherapy, nine for other reasons, such
as parenteral feeding, bone-marrow transplantation, hemody-
namicmonitoring of shock and for three patients the indication
of the catheter could not be ascertained. One control subject
had a CVC for hemodynamic monitoring of a septic shock in
the month before the index date.
Malignancy
For all cancer patients (including cancer diagnosed more than
5 years ago), taking also cancer among non-participants into
account (one of two cases and one of 540 control subjects) and
assuming a CVC was absent for non-participants, the crude
odds ratio was 17.9 (ORcrude 17.9, 95% CI: 12.0–26.7) and 7.7
for cancer patients without a CVC (ORcrude 7.7, 95% CI: 4.6–
13.0).
Table 1 Risk associated with central venous catheter (CVC) and active malignancy
Patients
(n ¼ 179)
Control
subjects
(n ¼ 2399)
Odds ratio
(95% CI)
Adjusted odds
ratio (95% CI)*
CVC
CVC absent 137 2398 1 (reference) 1 (reference)
CVC present 42 1 735 (100–5381) 1136 (153–8448)
Active malignancy
All participants, including CVC
Malignancy absent 121 2322 1 (reference) 1 (reference)
Malignancy present 46 35 25.2 (15.7–40.6) 43.6 (25.5–74.6)
All participants, CVC excluded
Malignancy absent 114 2321 1 (reference) 1 (reference)
Malignancy present 18 35 10.5 (5.8–19.1) 18.1 (9.4–35.1)
*Adjusted for age and sex.
Patients with cancer longer than 5 years ago are excluded from this analyses (nine cases and 38 control subjects), as well as three cases and four
control subjects of whom date of diagnosis was unknown.
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Among the 167 patients, 46 (27.5%) had a history of active
malignancy prior to the venous thrombosis, as compared with
35 (1.5%) of the 2357 control subjects (Table 1). The OR for
active malignancy was 25.2 (ORcrude 25.2, 95% CI: 15.7–40.6).
After adjustment for age and sex, the OR became 43.6 (ORadj
43.6, 95% CI: 25.5–74.6). The adjusted OR of venous
thrombosis for active malignancy in the absence of a CVC
was 18.1 (ORadj 18.1, 95% CI: 9.4–35.1; Table 1).
Of 46 patients with active cancer, 27 women and 19 men,
including patients with a CVC, 16 had gastro-intestinal cancer
(35%), 10 hematological cancer (22%) and four patients had
lung cancer (9%). Seven of 27 women had breast cancer and
three had ovarian cancer (26% and 11% of female patients
with active cancer respectively). There were no women with
cervix cancer, and no men with prostate cancer among the 19
men with cancer. Six patients had other types of cancer (13%).
Of 35 control subjects with active cancer three had gastro-
intestinal cancer (9%), two hematological cancer (6%) and one
lung cancer (3%). Nine of 23 women had breast cancer (39%),
two women ovarian cancer (9%) and one woman cervix cancer
(4%). Six of 12 men had prostate cancer (50%). Eleven control
subjects had other types of cancer (32%).
Among patients with active cancer without a CVC, the OR
of venous thrombosis was 11.5 in the presence of distant
metastases compared with active cancer patients without
distant metastases (ORadj 11.5, 95%CI: 1.6–80.2). The analysis
was limited to those with solid tumors, i.e. 15 cases and
29 control subjects.
Acquired risk factors
The analysis of other acquired risk factors was restricted to
individuals without a CVC, including 137 patients and 2398
control subjects. Cancer patients without a CVCwere included
in this analysis. Several risk factors, which play an important
role in the risk of venous thrombosis of the leg, such as surgery
and immobilization (plaster) also increased the risk for deep
venous thrombosis of the arm (Table 2). Injury also increased
the risk although not significantly. Additional analyses in
which adjustment for each of these risk factors and for active
cancer was made, led to similar OR. Only slightly more
patients (16.9%) were performing unusual heavy exercise in
the 3 months prior to the index date compared with control
subjects (13.5%). Travel by car, bus, train or plane in the
3 months before the index date did not clearly affect the risk of
upper extremity deep venous thrombosis. The adjusted OR for
travel by plane alone was 0.9 (95% CI: 0.4–2.3; five cases and
98 control subjects). There was no increase in risk for
individuals with a BMI > 25 kg m)2 compared with individ-
uals with a BMI < 25 kg m)2. The OR associated with a
family history of venous thrombosis was 2.8 (ORadj 2.8, 95%
CI: 1.6–4.9). Oral contraceptive use and puerperium increased
the risk of upper extremity venous thrombosis among women,
whereas HRT did not increase the risk. Restriction of the
above analyses to 124 objectively diagnosed cases gave similar
results.
Prothrombotic mutations
Overall the allele frequency of FV Leiden among control
subjects was 2.9%. There were 17 heterozygotes for the FV
Leiden mutation out of 144 patients (11.8%) and 108 of 2018
control subjects (5.4%). No homozygotes for the FV Leiden
mutation were found among patients and four (0.2%) among
control subjects. Including the participants with CVC the risk
of thrombosis in the presence of the FV Leiden mutation was
Table 2 Acquired risk factors for upper extremity venous thrombosis within 3 months before index date, excluding users of a central venous catheter
Risk factor
Patients
(n ¼ 137)
Control subjects
(n ¼ 2398)
Odds ratio
(95% CI)*
Adjusted odds
ratio (95% CI)*
Surgery upper extremity 2 3 11.8 (2.0–71.0) 13.1 (2.1–80.6)
Surgery elsewhere 10 38 5.0 (2.4–10.3) 4.7 (2.2–9.7)
Immobilization arm (plaster) 3 7 7.6 (2.0–29.9) 7.0 (1.7–29.5)
Injury upper extremity 4 30 2.4 (0.8–6.9) 2.1 (0.7–6.2)
Unusual exercise 23 303 1.3 (0.8–2.1) 1.5 (1.0–2.1)
Travel by car, bus, train, plane 18 257 1.2 (0.7–2.1) 1.3 (0.8–2.2)
body mass index
< 25 kg m)2 61 770 1 (reference) 1 (reference)
25–30 kg m)2 56 1175 1.5 (0.9–2.7) 1.2 (0.7–2.2)
> 30 kg m)2 17 328 0.9 (0.5–1.6) 0.9 (0.5–1.6)
Family history 17 107 3.0 (1.8–5.2) 2.8 (1.6–4.9)
Women 18–49 years n ¼ 48 n ¼ 534
Oral contraceptive use 28 176 2.8 (1.6–5.2) 2.0 (1.1–3.8)
Pregnancy 0 9 – –
Puerperium 1 2 5.7 (0.5–63.6) 3.1 (0.3–35.5)
Women 40–69 years n ¼ 44 n ¼ 947
Hormone replacement therapy 5 90 1.2 (0.5–3.1) 1.2 (0.5–3.2)
Information of all risk factors available for more than 95% of patients and for more than 93% of control subjects.
*Reference group for each risk factor is the group without the risk factor.
Adjusted for age and where applicable for sex.
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2.2-fold increased (ORadj 2.2, 95% CI: 1.3–3.8). The allele
frequency of the prothrombin G20210A mutation among
control subjects was 1.0%. Seven patients (4.9%) had the
heterozygous (20210 GA) variant compared with 42 control
subjects (2.1%). No homozygotes for the prothrombin
G20210A mutation were found. The risk of thrombosis in
the presence of the prothrombin G20210A mutation was
2.3-fold increased (ORadj 2.3, 95% CI: 1.0–5.2). Two control
subjects were double heterozygotes.
Malignancy and prothrombotic mutations
We evaluated the joint effect of the FV Leiden mutation and
the prothrombin 20210Amutation and active malignancy after
exclusion of patients with a CVC (Table 3). The OR for
carriers of a prothrombotic mutation without a malignancy
was 2.7 (ORadj 2.7, 95%CI: 1.6–4.7; Table 3). Individuals with
only malignancy had an OR of 12.6 (ORadj 12.6, 95% CI: 5.4–
29.4) compared with non-carriers without malignancy. Carriers
of a prothrombotic mutation who also had cancer had a OR of
177.1 (ORadj 177.1, 95% CI: 17.4–1806.1). This implies that
cancer patients with a prothrombotic mutation had a 20-fold
increased risk of venous thrombosis compared with non-
carriers with cancer (ORadj 20.0, 95% CI: 1.5–273.7). When
patients with a CVC were included, cancer patients with a
prothrombotic mutation had a sixfold increased risk of venous
thrombosis compared with non-carriers with cancer (ORadj 6.0,
95% CI: 0.6–62.0).
Acquired risk factors and prothrombotic mutations
Oral contraceptive users without a prothrombotic mutation
had an OR of 1.8 (ORadj 1.8, 95%CI: 0.8–3.9). In the presence
of a prothrombotic mutation we found an OR of 9.2 for oral
contraceptive users compared with non-users without a muta-
tion (ORadj 9.2, 95% CI: 2.8–30.2; Table 4). Users of HRT
without a prothrombotic mutation had an OR of 1.6 (ORadj
1.6, 95% CI: 0.5–4.7), which increased to 5.4 in the presence of
a prothrombotic mutation (ORadj 5.4, 95% CI: 0.6–47.8;
Table 4).
Table 3 Active malignancy, prothrombotic mutations, and the risk of arm thrombosis, excluding users of a central venous catheter
Factor V Leiden/
prothrombin
20210A
Active
cancer
Patients
n ¼ 109
Control
subjects
n ¼ 1987
Odds ratio
(95% CI)
Adjusted odds
ratio (95% CI)*
No No 78 1806 1 (reference) 1 (reference)
No Yes 9 28 7.4 (3.4–16.3) 12.6 (5.4–29.4)
Yes No 19 152 2.9 (1.7–4.9) 2.7 (1.6–4.7)
Yes Yes 3 1 69.5 (7.1–675.4) 177.1 (17.4–1806.1)
DNA-samples were available for 109 of 137 patients without CVC and 1987 of 2398 control subjects without CVC.
*Adjusted for age and sex.
Table 4 Oral contraceptive (OC) use, hormone replacement therapy (HRT) at index date, bodymass index (BMI: kg m)2), prothrombotic mutations, and
the risk of upper extremity venous thrombosis, excluding users of central venous catheter
Factor V Leiden/
prothrombin
20210A Patients
Control
subjects
Odds ratio*
(95% CI)
Adjusted OR
(95% CI)
OC Yes Yes 6 11 10.9 (3.5–33.8) 9.2 (2.8–30.2)
HRT§ Yes Yes 1 5 4.4 (0.5–37.8) 5.4 (0.6–47.8)
Surgery– Yes Yes 2 4 11.0 (2.0–60.6) 12.6 (2.2–73.5)
Surgery
OC** Yes Yes 3 3 19.9 (3.7–106.2) 13.7 (2.5–76.2)
HRT Yes Yes 1 1 27.8 (1.7–454.9) 29.4 (1.8–490.3)
BMI (kg m)2) < 25 Yes 3 19 2.1 (0.6–7.2) 2.0 (0.6–6.9)
25–30 Yes 5 16 4.1 (1.4–11.5) 4.6 (1.6–13.5)
> 30 Yes 4 3 17.4 (3.8–79.7) 23.0 (4.9–109.1)
Analysis for participants with DNA available (>82% of cases and >84% of control subjects) and who filled in the specific question in the
questionnaire.
*Reference group for each risk factor is the group with neither risk factor present.
Adjusted for age and where applicable for sex.
Women 18–49 years: 42 patients and 452 control subjects.
§Women 40–69 years: 34 patients and 793 control subjects.
–All participants: information available 112 patients and 2003 control subjects.
**Women 18–49 years: 47 patients and 527 control subjects.
Women 40–69 years: 41 patients and 909 control subjects.
All participants: information available for 133 patients and 2253 control subjects.
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Patients without a prothrombotic mutation undergoing
surgery had an increased risk of venous thrombosis of the arm
(OR 3.5, 95% CI: 1.4–8.8). Carriers of a prothrombotic
mutation, women using oral contraceptives and HRT or
individuals with a BMI over 25 kg m)2 had a higher risk of
upper extremity venous thrombosis when in a postoperative
period of up to 3 months (Table 4). The OR for obese people
undergoing surgery compared with non-obese people under-
going surgery is 7.1 (95% CI: 1.3–37.8).
Discussion
In this population-based case–control study the overall risk of
upper extremity venous thrombosis was 18-fold increased in
patients with cancer (including cancer diagnosed more than
5 years ago). Cancer patients without a CVC had an eightfold
increased risk whereas a CVC increased the risk of arm
thrombosis 1100-fold. Patients with active cancer and a
prothromboticmutation had a 20-fold increased risk compared
with patients with active cancer and without a prothrombotic
mutation. Several risk factors for deep vein thrombosis of the
lower extremity, such as prothrombotic mutations, surgery,
immobilization of the arm (plaster cast), oral contraceptive use
and family history, also affected the risk of arm thrombosis.
The risk in the presence of injury and during puerperium
increased, but not significantly. However, some risk factors,
such asHRT, obesity and travel did not increase the risk of arm
thrombosis. For several risk factors this risk was enhanced in
the presence of prothrombotic mutations or when undergoing
surgery.
Central venous catheter and malignancy
Twenty-three percent of the thrombosis patients had a CVC,
which is therefore by far the most important prevalent risk
factor for upper extremity thrombosis; this confirms two
studies also including consecutive, unselected patients descri-
bing a incidence of 30% [10,16].
The risk of upper extremity venous thrombosis in cancer
patients is increased mainly but not exclusively because of
CVCs. Whereas 61% of the patients with a malignancy had a
CVC, cancer patients without a CVC had an eightfold
increased risk of venous thrombosis of the arm, similar to the
risk of venous thrombosis of the leg or pulmonary embolism
[14]. A previous case-control study found a 2.6-fold increased
risk for cancer patients [10]. In the latter patients with arm
complaints but not objectively diagnosed venous thrombosis
participated as control subjects. This may explain the difference
as more control subjects suffered from cancer (9.7% vs. 1.5%
active cancer in the MEGA-study).
Compared with cancer patients with venous thrombosis of
the leg or pulmonary embolism, we found relatively more arm
thrombosis patients with hematological cancer and cancer of
the esophagus or stomach [14]. These patients received
chemotherapy byCVC [data not shown]. Additionally, patients
with esophagus or stomach cancer usually receive parenteral
nutrition by CVC after surgery thereby increasing the risk of
venous thrombosis. The distribution of types of cancer in
patients without a CVC is similar as shown before in patients
with deep venous thrombosis or pulmonary embolism [14].
Cancer patients with distant metastases had a 12-fold
increased risk of venous thrombosis compared with cancer
patients without distant metastases. In the analysis of distant
metastases, type of cancer and the combined presence of cancer
and prothrombotic mutations we defined active cancer as
cancer diagnosed within 5 years before the index date. This
might cause slight misclassification because we did not verify
the activity of the malignancy in the medical records. Cancer in
remission could have been more often classified as active
cancer, which could have led to underestimation of risks.
Acquired risk factors
Risk factors that play a role in deep venous thrombosis of the
leg or pulmonary embolism such as surgery, immobilization
(plaster cast) and oral contraceptive use also increased the risk
of upper extremity venous thrombosis in the MEGA-study.
HRT did not clearly increase the risk. Earlier reports were
inconclusive on hormone use [8,10,17], probably because of
small sample size and inclusion of referred selected patients.
A frequently described risk factor of upper extremity venous
thrombosis is unusual exercise, especially in individuals with
well developed thoracic musculature or anomalies leading to a
narrow thoracic outlet. We found a slight increase in risk of
upper extremity venous thrombosis for individuals performing
unusual exercise, in accordance with another case–control
study [10]. Although much attention is usually paid to the
thoracic outlet syndrome [2], only for one patient in our study
this syndrome was spontaneously reported in the discharge
letter.
It has been suggested in a case-series of five patients that air
travel can contribute to the development of upper extremity
venous thrombosis [18]. We did not find an increase in risk for
travel by car, bus, train or plane, neither was there an increase
in risk for travel by plane alone.
Malignancy and prothrombotic mutations
Patients with cancer and a prothrombotic mutation had a
highly increased risk of venous thrombosis comparedwith non-
carriers without cancer. A recent study of breast cancer patients
with CVCs found a sixfold increased risk of venous thrombosis
for carriers of the FV Leiden mutation compared with non-
carriers, similar to our results for overall cancer [19].
Other acquired risk factors and prothrombotic mutations
Odds ratios of venous thrombosis for the FV Leiden
mutation and the prothrombin 20210A mutation were slightly
higher in an Italian case-control study, which is likely to be
due to a selected patient group in the latter [8]. We found a
synergistic effect between oral contraceptive use or HRT and
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prothrombotic mutations. Both these findings were analogous
to those described earlier in patients with upper and lower
extremity venous thrombosis or a pulmonary embolism
[20–22]. High risks were seen for surgical patients particularly
when they used exogenous hormones or were obese.
Although our study is one of the largest studies of patients
with deep venous thrombosis of the arm, a limitation of the
study is the small number of cases. This small number is a
reflection of the low incidence of deep venous thrombosis of the
arm. As a consequence the confidence intervals of several of
our analyses are wide, indicating unstable estimates of the OR.
However, as this is one of the few studies comparing patients
with arm thrombosis to the general population and one of the
first studies evaluating interaction between risk factors in
patients with arm thrombosis, this may give indications for
further study.
Clinical implications
As the incidence of arm thrombosis is only 4% of the total
incidence of venous thrombosis, the absolute risk remains very
small for all risk factors except CVCs. Screening for genetic risk
factors in the general population in order to avoid arm
thrombosis by subsequent prophylactic treatment is therefore
not an issue. Although risks are increased in surgical patients,
patients using oral contraception or HRT and cancer patients,
screening for prothrombotic mutations does not seem to be
useful in these patient groups either.
Assuming an incidence of venous thrombosis of one per
1000 per year, in patients with a CVCwe would expect a yearly
absolute incidence of: 1136 (OR) · 1/1000 (incidence venous
thrombosis overall) · 1/25 (4%) ¼ one per 22 patients with a
CVC. These figures are in line with a recent publication in
which we followed patients with CVC’s [23]. In this study we
found a cumulative incidence of clinically manifest thrombosis
of 7.1% after 1 year of follow up. A recent review study
describes cumulative incidences from 0% to 12% [24]. For
patients with FV Leiden or the prothrombin 20210A mutation
the risk is 2.7-fold increased compared with patients with a
CVC but without these mutations [23]. Prophylactic anticoag-
ulation in patients with a CVC is not yet a standard procedure.
Three studies have shown a beneficial effect of anticoagulant
prophylaxis in cancer patients with CVCs [25–27]. More recent
studies failed to show a beneficial effect thus far in cancer
patients [28–30]. However, complete data of the latter studies
have to be awaited. A review on CVC related thrombosis
concluded that routine prophylaxis for patients with a CVC is
still debatable [24]. In view of the high risk of arm thrombosis
for patients with a CVC future trials should explore which
patients with a CVC could benefit from anticoagulant
prophylaxis.
Conclusion
Generally, risk factors for venous thrombosis of the arm are the
same as those for venous thrombosis of the leg, apart from
HRT, obesity and travel. A specific risk factor for arm
thrombosis is a the presence of a CVC.
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